Key takeaways from the updated multidisciplinary European MASLD guidelines
Paul Horn1,2, Frank Tacke1
1Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
New European guidelines offer comprehensive management strategies for metabolic dysfunction-associated steatotic liver disease (MASLD). Key recommendations include lifestyle changes, treating cardiometabolic risk factors, and novel therapies like incretin mimetics and resmetirom for metabolic dysfunction-associated steatohepatitis (MASH).
Area of Science:
- Hepatology and Gastroenterology
- Endocrinology and Metabolism
- Clinical Practice Guidelines
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern.
- Existing management strategies require updated, evidence-based clinical practice guidelines.
- The European Association for the Study of the Liver, Diabetes, and Obesity have collaborated to address this need.
Purpose of the Study:
- To present new European clinical practice guidelines for MASLD management.
- To provide detailed recommendations on diagnosis, risk stratification, monitoring, treatment, and prevention.
- To incorporate recent advancements in pharmacological and non-invasive diagnostic approaches.
Main Methods:
- Development of guidelines by three major European scientific societies.
- Review and synthesis of current evidence on MASLD diagnosis and management.
- Inclusion of recommendations for lifestyle interventions, cardiometabolic risk factor management, and novel pharmacotherapies.
Main Results:
- Guidelines emphasize lifestyle interventions (weight reduction, diet, exercise, alcohol abstinence) as foundational.
- Incretin mimetics (semaglutide, tirzepatide) show promise for ameliorating metabolic dysfunction-associated steatohepatitis (MASH).
- Novel recommendations include non-invasive tests (NITs) for screening and fibrosis detection, and potential use of resmetirom for MASH fibrosis (≥F2).
Conclusions:
- The new guidelines provide a comprehensive framework for MASLD management.
- A multi-faceted approach combining lifestyle, risk factor control, and targeted therapies is recommended.
- The guidelines highlight the evolving landscape of MASLD treatment, including new pharmacological options and non-invasive monitoring tools.
Related Concept Videos
Diagnostic and Statistical Manual of Mental Disorders (DSM)
Chronic Pancreatitis II: Collaborative Care
Assessment:
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...


